Package 49401-088-02

Brand: benlysta

Generic: belimumab
NDC Package

Package Facts

Identity

Package NDC 49401-088-02
Digits Only 4940108802
Product NDC 49401-088
Description

1 SYRINGE in 1 CARTON (49401-088-02) / 1 mL in 1 SYRINGE (49401-088-01)

Marketing

Marketing Status
Marketed Since 2017-07-20
Brand benlysta
Generic belimumab
Sample Package No

Linked Drug Pages (1)

Raw FDA Data

View complete raw FDA NDC JSON payload
{"route": ["SUBCUTANEOUS"], "spl_id": "379d7f58-8f17-44b3-8336-6fe8ef015aed", "openfda": {"nui": ["N0000182156", "N0000182637", "N0000182636"], "unii": ["73B0K5S26A"], "rxcui": ["1656395", "1656398", "1656400", "1656402", "1939296", "1939299", "1939346", "1939348"], "spl_set_id": ["2fa3c528-1777-4628-8a55-a69dae2381a3"], "pharm_class_pe": ["Decreased B Lymphocyte Activation [PE]"], "pharm_class_epc": ["B Lymphocyte Stimulator-specific Inhibitor [EPC]"], "pharm_class_moa": ["B Lymphocyte Stimulator-directed Antibody Interactions [MoA]"], "manufacturer_name": ["GlaxoSmithKline LLC"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 SYRINGE in 1 CARTON (49401-088-02)  / 1 mL in 1 SYRINGE (49401-088-01)", "package_ndc": "49401-088-02", "marketing_start_date": "20170720"}, {"sample": false, "description": "4 SYRINGE in 1 CARTON (49401-088-35)  / 1 mL in 1 SYRINGE (49401-088-01)", "package_ndc": "49401-088-35", "marketing_start_date": "20170720"}, {"sample": false, "description": "4 SYRINGE in 1 CARTON (49401-088-47)  / 1 mL in 1 SYRINGE (49401-088-42)", "package_ndc": "49401-088-47", "marketing_start_date": "20170720"}, {"sample": false, "description": "1 SYRINGE in 1 CARTON (49401-088-50)  / 1 mL in 1 SYRINGE (49401-088-42)", "package_ndc": "49401-088-50", "marketing_start_date": "20170720"}, {"sample": true, "description": "1 SYRINGE in 1 CARTON (49401-088-61)  / 1 mL in 1 SYRINGE", "package_ndc": "49401-088-61", "marketing_start_date": "20200602"}], "brand_name": "BENLYSTA", "product_id": "49401-088_379d7f58-8f17-44b3-8336-6fe8ef015aed", "dosage_form": "SOLUTION", "pharm_class": ["B Lymphocyte Stimulator-directed Antibody Interactions [MoA]", "B Lymphocyte Stimulator-specific Inhibitor [EPC]", "Decreased B Lymphocyte Activation [PE]"], "product_ndc": "49401-088", "generic_name": "belimumab", "labeler_name": "GlaxoSmithKline LLC", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "BENLYSTA", "active_ingredients": [{"name": "BELIMUMAB", "strength": "200 mg/mL"}], "application_number": "BLA761043", "marketing_category": "BLA", "marketing_start_date": "20170720", "listing_expiration_date": "20271231"}